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A B S T R A C T
Tritium-labelled ﬂuoroazomycin arabinoside, [3H]-FAZA, is a useful probe for the investigation of
hypoxia, furthermore it is safer and easier to handle than the PET tracer [18F]-FAZA when used in cell
based assays. The only known synthesis of deuterium- and tritium-labelled FAZA was re-investigated
and optimized. Then, a new and improved synthesis of [2H]-FAZA was developed as a model process for
tritium radiolabelling. This novel synthesis is expected to greatly facilitate access to [3H]-FAZA.
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Most tumour types feature hypoxic (low oxygen) regions, and
in some neoplastic pathology hypoxia may be present in up to 60%
of patients [1]. Generally, tumours with high hypoxic volumes
have a poor prognosis because they are associated with an
aggressive phenotype and increased risk of metastasis [2].
Furthermore these tumours tend to respond poorly to radiothera-
py and/or chemotherapy [3]. Accordingly, tumour hypoxia is a key
driver of tumour growth, proliferation, maintenance and resis-
tance to therapy. For the reasons above, a robust and reliable
method to identify hypoxia in tumours would have signiﬁcant
value as a predictive biomarker to identify patients and tumours
likely to be non-responsive to chemotherapy and radiotherapy.
PET imaging is a particularly attractive option to study hypoxia, as
it is non-invasive, quantitative, does not require biopsy tissue, and
can provide information across the entire tumour [4]. In the last
decades, several PET and SPECT hypoxia markers have been
developed, many of which are based on the use of nitroimidazole
derivatives as ﬁrst proposed by Chapman in 1979 [5]. Nitroimi-
dazole tracers are able to detect tumour hypoxia since they
accumulate in hypoxic tissues by a bio reductive linkage* Corresponding author at: Kosterlitz Centre for Therapeutics, Institute of
Medical Sciences, University of Aberdeen, Foresterhill, AB25 2ZD, Scotland, UK.
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Open access under CC BY license.mechanism. The nitroso and hydroxylamino-imidazole metabo-
lites produced in hypoxic tissues covalently bind to cellular
molecules therefore trace quantities of labelled compounds are
chemically bound to hypoxic cells [6].
Among the ﬂuorinated hypoxia PET tracers, [18F]-FAZA,
(ﬂuoroazomycin arabinoside 1, Fig. 1) developed by Kumar in
1998 [7], was found to be useful for imaging hypoxia in various
tumours such as glioblastoma, with a remarkably high tumour-to-
background and it can be considered the ‘‘gold standard’’ for the
measurement of tissue hypoxia [8].
Although 18F-FAZA is nowadays produced in many clinical PET
facilities and the 18F radiosynthesis has been widely investigated,
optimized, and automated [9], the deuterium (2) and tritium
labelled (3) parent compounds are not commercially available.
[3H]-FAZA is an attractive molecular tool for in vitro studies and
comparison of different and novel hypoxia tracers. Moreover it is
safer and much easier to handle than [18F]-FAZA when used in cell
based assays. Last but not least, [3H]-FAZA can be conveniently
stored for many years (tritium half-life is 12.32 years).
Here we report our studies towards the synthesis of the
deuterium labelled [2H]-FAZA 2, which was obtained by two
different synthetic strategies, as a model process for [3H]-FAZA
synthesis. The ﬁrst route is based on a modiﬁcation of the Kumar
method [7], the only one reported to date for the synthesis of 2 and
3, which unfortunately in our hands could not be reproduced as
originally described by the authors. The second is an optimized
alternative route to 2 based on the use of different protective
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Fig. 1. FAZA and its labelled derivatives.
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Scheme 2. Reagent and conditions: (i) TfOTES, toluene (79%) and (ii) Pyridine, reﬂux
(quantit.).
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Scheme 3. Synthesis of FAZA. Reagent and conditions: (i) (1) TBDPSCl, Py, 20 8C; (2)
Ac2O, rt (71% over 2 steps); (ii) 4, TfOTES, CH3CN, 8 8C (72%); (iii) KF, benzoic acid,
CH3CN, reﬂux (80%); and (iv) DAST, DCM, rt (50%); v: 2 N NH3 in MeOH, 4 8C (60%).
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FAZA 3.
2. Results and discussion
2.1. Synthesis of FAZA 1
Our synthesis of FAZA (1) is based on the coupling of 2-nitro-1-
(triethylsilyl)imidazole 4 with the protected arabinose derivative 5
(Scheme 1), according to the strategy published by Schweifer and
Hammerschmidt [10]. The key intermediate 6 was then converted
into FAZA (1) following the pathway proposed by Kumar and co-
workers [7].
Both starting substrates 4 (Scheme 2) and 5 (Scheme 3) had to
be prepared. Hexaethyldisilazane 9 (Scheme 2, Eq. 1) was prepared
from (triethylsilyl)amine 7 and chlorotriethylsilane 8 in the
presence of a catalytic amount of triethylsilyl triﬂate in dry
toluene. A reﬂuxing mixture of 2-nitroimidazole (10) and
hexaethyldisilazane 9 in pyridine afforded quantitatively the
desired substrate 4 (Scheme 2, Eq. 2) [10].
The synthesis of FAZA (1) (Scheme 3) started from D-arabinose
(11) which was fully protected obtaining a mixture of anomeric
acetates 5 (a:b = 60:40) [10]. The coupling reaction between 2-
nitro-1-(triethylsilyl)imidazole 4 and the anomers 5 afforded the
nitroimidazole D-arabinofuranose derivative 6 that was subjected
to selective deprotection of the primary hydroxyl group in order to
obtain the compound 12 [10]. The subsequent deoxyﬂuorination
was achieved using diethylaminosulfur triﬂuoride (DAST) in DCM,
which gave the protected ﬂuorinated precursor 13 that was then
fully deprotected with ammonia in methanol giving FAZA (1) [7].
2.2. Synthesis of [2H]-FAZA 2
Once the synthesis of FAZA 1 was optimized, we switched to the
synthesis of the deuterated analogue 2, initially following the
procedure reported by Kumar and co-workers [7]. The retro-
synthetic approach (Scheme 4) involved the oxidation of the
alcohol 12 to the corresponding aldehyde 14a, followed by
reduction with a deuterating agent to provide the deuterated
alcohol 15a. Subsequently, using the same reactions used for the
synthesis of FAZA, we planned to obtain our target molecule 2.
However, in our hands the oxidation step from 12 to 14a
(Scheme 5) could not be reproduced following the conditions
(Pﬁtzner–Moffatt oxidation) described by Kumar et al. [7]. It is
worth noting that the Kumar’s protocol involved the treatment of
12 ‘‘dissolved in anhydrous dimethyl sulfoxide’’ with DCC followedScheme 1. Retro-syntby cooling on an ice bath, which not surprisingly in our hands
resulted in a solid mixture and no reaction. Upon heating until
melting of the mixture, we observed the formation of a complex
mixture of unidentiﬁed products, in which we could not identify
the desired aldehyde 14a.
Stimulated by the need of a more effective and reliable
procedure, we ﬁrst modiﬁed the conditions of the Pﬁtzner–Moffatt
oxidation as shown in Scheme 6 and Table 1, entry 1. We obtained
the desired aldehyde 14a but also a consistent quantity of the by-
product 14b, arising from elimination of the acetate in position 3 of
the arabinose ring. Unfortunately these two aldehydes could be
separated neither by ﬂash chromatography nor by HPLC.
At that point we investigated different oxidation conditions
with the aim of suppressing the formation of the by-product 14b
(Table 1, entries 2–6). Eventually, the best conditions we were able
to identify afforded a more acceptable 30% of the undesired
aldehyde 14b (entry 3).
The inseparable mixture of the two aldehydes 14a and 14b
(Scheme 7) was then reduced with deuterated sodium cyanobor-
ohydride (NaBD3CN) affording the two deuterated alcohols 15a andhesis of FAZA 1.
Scheme 4. Retro-synthesis of [2H]-FAZA 2.
Scheme 5. Attempted oxidation of 12–14a under ‘‘Kumar conditions.’’ Reagent and
conditions: (i) DMSO, DCC, Cl2CHCO2H, oxalic acid, DCM.
C. Zanato et al. / Journal of Fluorine Chemistry 155 (2013) 110–11711215b. An HPLC separation provided 15a that was deoxyﬂuorinated
with DAST and deprotected with NH3/MeOH giving [
2H]-FAZA 2.
The preparation of 3-deoxy-3,4-didehydro-5-aldehydes such as
14b is a known transformation in carbohydrate chemistry, but it
generally involves the treatment of 5-formyl-furanoses having an
anti-stereochemistry at carbons 2,3 (ribose and arabinose deriva-
tives) with organic bases such as TEA or DABCO [11], and does not
usually occur in the absence of any basic treatment.
In order to better understand the mechanism involved in the
spontaneous formation of the elimination by-product, we per-
formed an NMR study (Fig. 2) monitoring the Pﬁtzner–Moffatt
oxidation reaction (DMSO-d6, EDC, Cl2CHCO2H in DMSO-d6/
benzene-d6 1:1). We recorded a series of NMR spectra starting
from 0 8C and progressively increasing the temperature to 25 8C. In
order to monitor the formation of the two aldehydes 14a,b we
focussed our attention on the corresponding CHO protons, which
have diagnostic low ﬁeld chemical shifts (9.87 ppm for 14a and
9.81 ppm for 14b in DMSO-d6).
At 0 8C, 5 8C, 10 8C, 158 and 20 8C the reaction did not proceed as
it can be seen by the absence of any CHO signal in spectra 1–5,
Fig. 2. When the temperature was increased to 25 8C the aldehyde
proton of 14a (signal at 9.87 ppm) started to become visible,Scheme 6. Screening of conditions for the P
Table 1
Screening of conditions for the Pﬁtzner-Moffatt oxidation of 12–14a,b.
Entry Reagents Solvents and
1 DMSO, EDC, Cl2CHCO2H DMSO/benze
2 DMSO, EDC, Py.TFA DMSO/benze
3 DMSO, EDC, Py.TFA DMSO/benze
4 DMSO, (COCl)2, Et3N DCM, 78 8C
5 TEMPO, TCC DCM, 0 8C to
6 DMP, Py DCM, 0 8C to
7 TPAP, NMO DCM rt 
a Reactions quenched with water. Key: EDC = N-(3-dimethylaminopropyl)-N-ethylca
nuric Acid; DMP = Dess-Martin periodinane.meaning that just the desired product was forming (spectra 6–12,
Fig. 2). After 3 h the reaction was quenched by addition of
deuterated water. The NMR spectrum was recorded immediately
afterwards (spectra 13 Fig. 2), showing the presence of two
aldehyde signals (4:6 ratio), the new signal corresponding to the
14b aldehyde proton at 9.81 ppm. This NMR study therefore
demonstrates that the elimination by-product 14b is formed
exclusively during the reaction quenching.
Based on the evidence above, we investigated the reaction
quenching by testing a number of different conditions after
performing the oxidation under the optimized conditions of
Table 1, entry 3. Direct evaporation at reduced pressure without
any quenching unexpectedly afforded 14b as the sole product.
Filtration on silica gel or Celite1 without quenching afforded a
14a:14b mixture in 1:9 ratio. Addition of NH4Cl instead of water
afforded 14a:14b in 7:3 ratio, whereas the use of even mildly basic
water solutions produced partial hydrolysis of the acetyl groups.
Finally, changing the organic solvent used for the extraction from
EtOAc to Et2O or DCM had no tangible effect.
The synthesis above is affected by a number of drawbacks,
therefore we decided to investigate an alternative and more
convenient route to [2H]-FAZA 2. To overcome the elimination of
the 3-b-acetoxy group, which is a good leaving group, we focussed
our attention on the synthesis of the 2,3 O-PMB protected
arabinoside. In fact, we reasoned that elimination of a benzyloxy
group should be considerably less favoured than that of an acetoxy
group, therefore the elimination side-reaction could be suppressed
or limited. Unfortunately attempts to install the O-PMB protection
on deacetylated 6 (Scheme 3) failed when NaH and PMBCl or p-
methoxybenzyl trichloroacetimidate in combination with PPTS,
PTSA or BF3 were used.
A different strategy based on a 3-PMB protected acetate donor
was therefore investigated (Scheme 8). Starting from the readilyﬁtzner-Moffatt oxidation of 12–14a,b.
 conditionsa Ratio 14a:14b Yields
ne (1:1), 0–25 8C 40:60 70
ne (1:1), 0 8C No product None
ne (1:1), 0–25 8C 70:30 75
 0:100 80
 rt No product None
 rt No product None
No product None
rbodiimide; TEMPO = 2,2,6,6-Tetramethyl-1-piperidinyloxy; TCC = Trichloroisocya-
Scheme 7. Completion of the ‘‘Kumar-inspired’’ synthesis of [2H]-FAZA 2. Reagent and conditions: (i) NaBD3CN, EtOH (70%); (ii) DAST, DCM, rt (45%); and (iii) 2 N NH3 in MeOH,
4 8C (55%).
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Fig. 2. NMR study of Pﬁtzner–Moffatt oxidation.
Scheme 8. Reagent and conditions: (i) PMBCl, NaH, TBAI, DMF, 08 to rt (72%); (ii) aqueous TFA 50%, DCM (52%), rt; (iii) Ac2O, Py, rt (100%); (iv) 1-TES-2-nitroimidazole (4),
TfOTES, MeCN, 20 8C to 8 8C (76%); and (v) KF, PhCOOH, MeCN, 75 8C (95%).
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Scheme 9. Reagents and conditions: (i) EDC-HCl, Py-TFA, DMSO/benzene 1:1 (100%), rt; (ii) NaBD3CN or NaBH3CN, EtOH rt (75%); (iii) DAST, DCM, 0 8C to rt (35%); (iv) CAN,
acetone/H2O 4:1, rt (93%); and (v) NH3 2 M in MeOH, 4 8C (100%).
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arabinose 11 [12], the fully protected 3-PMB sugar 18 was obtained
in good yield using NaH, PMBCl and TBAI in anhydrous DMF. The
hydrolytic acetonide deprotection required extensive optimiza-
tion, because of the instability of the TBDPS and PMB groups in
aqueous hydrochloric and concentrate triﬂuoroacetic acid respec-
tively. Optimal conditions were found using aqueous TFA (50%) in
DCM as solvent. The lactol 19, obtained as a 1:1 mixture of
anomers, was then diacetylated with acetic anhydride in pyridine,
affording the diacetate glycosyl donor 20, again as an inseparable
anomeric mixture in quantitative yields. The glycosylation step
was accomplished by treating 20 with 1-triethylsilyl-2-nitroimi-
dazole and a catalytic amount of triethylsilyl triﬂate in anhydrous
acetonitrile at 8 8C affording the 2-nitromidazole glycoside 21 in
76% yield as a single a-anomer, thanks to the anchimeric
participation of the 2-b-acetate in the stabilization of the
intermediate oxocarbenium ion. The compound 21 was then O-
TBDPS deprotected with KF and the key alcohol intermediate 22
was therefore obtained.
As in the previous approach to 2 (see Scheme 7), the alcohol 22
was oxidized to the aldehyde 23 using EDC and DMSO (Scheme 9).
Gratifyingly, no elimination products were observed in this case.
The reduction with NaBD3CN gave the deuterated alcohol 24, that
was deoxyﬂuorinated with DAST to 25a in a rather modest 35%
yield, which could not be optimized further. The ﬂuoride 25a was
then oxidatively deprotected with CAN to the secondary alcohol
26a which was subjected to the ﬁnal deacetylation to provide the
target [2H]-FAZA 2 in satisfactory overall yields. The corresponding
non-deuterated compounds 25,26b were also obtained directly
from 22, eventually leading to FAZA 1.
3. Conclusions
We have conducted a detailed study on the synthesis of one of
the most important ﬂuorine-containing compounds in the realm of
molecular imaging, FAZA (1). An optimized approach to deuteri-
um-labelled FAZA (2) was developed as a model process which is
expected to greatly facilitate the synthesis of tritium-labelled FAZA
(3), a potentially very useful molecular probe for the biological
investigation of tumour hypoxia, whose use has been hithertohampered by its extremely limited availability and difﬁcult
preparation. Tritium-labelled FAZA had previously been obtained
by means of the same reducing agent used here albeit in tritium-
labelled form, i.e. NaB3H3CN [7], therefore we envisage that our
synthesis will be actually used for the preparation of [3H]-FAZA.
4. Experimental
4.1. General Information
1H (400.13 MHz), 13C (100.58 MHz) and 19F (376.45 MHz) NMR
spectra were recorded on a Bruker ADVANCE III spectrometer. 1H
NMR chemical shifts are reported relative to TMS, and the solvent
resonance was employed as the internal standard (CDCl3, d = 7.26).
13C NMR spectra were recorded with complete proton decoupling,
and the chemical shifts are reported relative to TMS with the solvent
resonance as the internal standard (CDCl3, d = 77.0).
19F NMR spectra
were recorded with complete proton decoupling. The following
abbreviations are used to describe spin multiplicity: s = singlet,
d = doublet, t = triplet, m = multiplet, dd = doublet–doublet,
dt = doublet–triplet, ddd = doublet–doublet–doublet, and br = broad
signal. All chemical shifts (d) are expressed in parts per million and
coupling constant (J) are given in Hertz. LC–MS experiments were
performed on an Agilent Technologies 1200 Series HPLC system
equipped with a DAD and a 6120 MS detector composed by a ESI
ionization source and a Single Quadrupole mass selective detector
using a Analytical C18 RP column (Phenomenex Luna, C18,
250 mm  4.60 mm, 5 m, 100 A´˚). HPLC puriﬁcations were performed
on the Agilent 1200 system using a semi preparative C18 RP column
(Phenomenex Luna, 250 mm  10.00 mm, 5 m, 100 A´˚). All reactions
were carried out in oven- or ﬂame-dried glassware under nitrogen
atmosphere, unless stated otherwise. All commercially available
reagents were used as received. Reactions were magnetically stirred
and monitored by TLC on silica gel (60 F254 pre-coated glass plates,
0.25 mm thickness). Visualization was accomplished by irradiation
with a UV lamp and/or staining with a ceric ammonium molybdate or
KMnO4 solution. Flash chromatography was performed on silica gel
(60 A˚, particle size 0.040–0.062 mm). Yields refer to chromatograph-
ically and spectroscopically pure compounds, unless stated other-
wise. Abbreviations used: DMSO for dimethylsulfoxide, DCM for
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DMF for dimethylformamide, Et2O for diethyl ether, Py for pyridine,
DMP for Dess-Martin periodinane, TFA for triﬂuoroacetic acid, TESOTf
for triethylsilyl triﬂuoromethanesulfonate, EDC for N-(3-dimethyla-
minopropyl)-N-ethylcarbodiimide, DAST for (diethylamino)sulfur
triﬂuoride, CAN for ammonium cerium(IV) nitrate, and TBAI for
tetrabuthylammonium iodide. Compounds 5, 6, 7, 9 and 12 were
synthesized as previously described [10]. The synthesis of compound
13 and its conversion to 1 were performed as previously described
[7].
4.2. (2S,3S,4S)-4-(acetyloxy)-5-formyl-2-(2-nitro-1H-imidazol-1-
yl)oxolan-3-yl acetate and (2S,3S)-5-formyl-2-(2-nitro-1H-imidazol-
1-yl)-2,3-dihydrofuran-3-yl acetate (14a and 14b)
The alcohol 12 (150 mg, 0.15 mmol) was dissolved in a mixture
of DMSO/benzene 1:1 (4.5 mL) and cooled to 0 8C. Pyridinium
triﬂuoroacetate (14.5 mg, 0.075 mmol) and EDC HCl (77.6 mg,
0.40 mmol) were added and the reaction mixture was allowed to
warm to r.t. After 2 h the reaction was quenched with water and
extracted with EtOAc (3  15 mL). The organic layers were washed
with brine (3  5 mL), dried over MgSO4, ﬁltered and the solvent
was evaporated under reduced pressure. An inseparable mixture of
the two aldheydes 14a and 14b was obtained (140 mg, ratio
14a:14b = 7:3) as a pale yellow oil and it was subjected to the next
step without further puriﬁcation. Rf 0.60 (EtOAc 100%); 1H NMR
(400 MHz, CDCl3, 14b signals are marked by *) d: 2.01 (s, 3H), 2.15
(s, 3H), 2.19 (s, 3H)*, 4.99 (s, 1H), 5.39 (d, J = 0.8 Hz, 1H), 5.44 (s,
1H), 5.59 (t, J = 2.6 Hz, 1H)*, 6.29 (d, J = 2.8 Hz, 1H)*, 6.75 (s, 1H),
7.10 (d, J = 2.3 Hz, 1H)*, 7.14 (s, 1H)*, 7.22 (s, 1H)*, 7.24 (d,
J = 1.1 Hz, 1H), 7.44 (d, J = 1.1 Hz, 1H), 9.66 (s, 1H)*, 9.77 (s, 1H).
4.3. (2S,3S,4R,5R)-4-(acetyloxy)-5-[hydroxy(2H1)methyl]-2-(2-
nitro-1H-imidazol-1-yl)oxolan-3-yl acetate (15a)
The inseparable crude mixture of the two aldehydes 14a and
14b was dissolved in ethanol (1.5 mL), cooled at 0 8C and NaBD3CN
(9.3 mg, 0.15 mmol) was added. The pH was adjusted to 4.5 adding
one or two drops of acetic acid and the mixture was allowed to
warm to r.t. and stirred overnight. The solvent was then removed
under reduced pressure and the residue was dissolved in EtOAc
(22 mL). The organic layer was washed with water (5 mL), brine
(5 mL), dried over MgSO4, ﬁltered and concentrated under reduced
pressure. A mixture of two alcohols 15a and 15b was separated by
HPLC (Semi-preparative C18 Luna column, Eluent: A: H2O, Eluent
B: CH3CN; in isocratic condition Eluent A: 80% and Eluent B: 20%;
retention time: 10.8 min). The collected fractions were concen-
trated under vacuum to give compound 15a (15.9 mg, 32% over
two steps) as a white foam. Rf 0.42 (EtOAc 100%); 1H NMR
(400 MHz, CDCl3) d: 2.03 (s, 3H), 2.20 (s, 3H), 3.91 (m, 1H), 4.54 (m,
1H), 5.16 (m, 1H), 5.47 (t, J = 1.7 Hz, 1H), 6.67 (d, J = 1.4 Hz, 1H),
7.24 (d, J = 1.0 Hz, 1H), 7.40 (d, J = 1.0 Hz, 1H); 13C NMR (100 MHz,
CDCl3) d: 20.6, 61.7 (t, J = 22 Hz, D), 76.5, 81.5, 88.1, 92.8, 122.0,
128.6, 169.0, 169.7; MS (ESI), calculated m/z C12H14DN3O8 330
[M]+, found m/z (relative intensity) 353 [M+Na]+ (75), 331 [M+H]+
(100).
4.4. (2S,3S)-5-[hydroxy(2H1)methyl]-2-(2-nitro-1H-imidazol-1-yl)-
2,3-dihydrofuran-3-yl acetate (15b)
Synthesized from the mixture of two aldehydes 14a and 14b as
15a (see above). Puriﬁed by HPLC (Semi-preparative C18 Luna
column, Eluent: A: H2O, Eluent B: CH3CN; in isocratic condition
Eluent A: 80% and Eluent B: 20%; retention time: 12.0 min). The
collected fractions were concentrated under vacuum to give
compound 15b (5.2 mg, 13% over two steps) as a white foam. Rf0.42 (EtOAc 100%); 1H NMR (400 MHz, CDCl3) d: 2.06 (s, 3H), 4.39
(m, 1H), 5.38 (m, 1H), 5.74 (m, 1H), 7.02 (d, J = 1.5 Hz, 1H), 7.20 (d,
J = 1.2 Hz, 1H), 7.32 (d, J = 1.1 Hz, 1H); MS (ESI), calculated m/z
C10H10DN3O6 270 [M]
+, found m/z (relative intensity) 293 [M+Na]+
(45), 271 [M+H]+ (100).
4.5. (2S,3S,4S,5S)-4-(acetyloxy)-5-[ﬂuoro(2H1)methyl]-2-(2-nitro-
1H-imidazol-1-yl)oxolan-3-yl acetate (16)
To an ice cooled solution of 15a (15 mg, 0.05 mmol) in
anhydrous DCM (0.2 mL), DAST (6.5 mL, 0.048 mmol) was added
drop wise under stirring. After 10 min the reaction was slowly
warmed to r.t. and stirred for additional 30 min. The mixture was
then cooled to 0 8C and MeOH (0.06 mL) was added to quench the
reaction. The solvent was removed under reduced pressure and the
crude product was puriﬁed by ﬂash chromatography (Hexane/
EtOAc 1:9) to give compound 16 (7.5 mg, 45%) as a pale yellow oil.
Rf 0.70 (EtOAc 100%); 1H NMR (400 MHz, CDCl3) d: 2.05 (s, 3H),
2.21 (s, 3H), 4.63 (m, 2H), 4.68 (m, 1H), 4.75 (m, 1H), 5.21 (m, 1H),
5.47 (t, J = 1.3 Hz, 1H), 6.70 (d, J = 1.7 Hz, 1H), 7.25 (d, J = 1.2 Hz,
1H), 7.38 (d, J = 1.1 Hz, 1H); 19F NMR (376.45 MHz, CDCl3) d:
228.9; 13C NMR (100 MHz, CDCl3) d: 20.4, 76.1, 81.2 (dt, J = 23.4,
75.2 Hz), 86.1 (d, J = 19.9 Hz), 86.2, 90.1, 121.8, 128.6, 169.0, 169.5;
MS (ESI), calculated m/z C12H13DFN3O7 332 [M]
+, found m/z
(relative intensity) 355 [M+Na]+ (50), 333 [M+H]+ (100).
4.6. (2S,3S,4S,5S)-2-[ﬂuoro(2H1)methyl]-5-(2-nitro-1H-imidazol-1-
yl)oxolane-3,4-diol (2H-FAZA, 2)
To neat compound 16 (3.8 mg, 0.013 mmol) cooled at 0 8C was
added a solution of anhydrous ammonia in MeOH 2 M (1 mL). The
reaction was left at 4 8C overnight. The solvent was removed under
reduced pressure and the crude product was puriﬁed by HPLC
(Semi-preparative C18 Luna column, Eluent: A: H2O, Eluent B:
CH3CN; in isocratic condition Eluent A: 90% and Eluent B: 10%;
retention time: 11 min). The collected fractions were concentrated
under vacuum to give compound 2 (1.7 mg, 55%) as a white solid.
Rf 0.56 (EtOAc 100%); 1H NMR (400 MHz, CD3OD) d: 4.12 (bs, 1H),
4.32 (s, 1H), 4.54 (m, 1H), 4.66 (m, 1H), 6.47 (bs, 1H), 7.16 (bs, 1H),
7.70 (bs, 1H); 19F NMR (376.45 MHz, CD3OD) d: 227.4; 13C NMR
(100 MHz, CD3OD) d: 75.8, 82.2, 82.8 (dt, J = 22.9, 76.2 Hz), 87.7 (d,
J = 21 Hz), 95.5, 124.0 126.9; MS (ESI), calculated m/z C8H9DFN3O5
248 [M]+, found m/z (relative intensity) 249 [M+H]+ (100).
4.7. {[(3aS,5R,6R,6aS)-6-[(4-methoxyphenyl)methoxy]-2,2-
dimethyl-tetrahydro-2H-furo[2,3-d][1,3]dioxol-5-yl]methoxy}(tert-
butyl)diphenylsilane (18)
To a solution of 17 (synthesized as previously reported [12],
2.6 g, 6.0 mmol) and p-methoxybenzyl chloride (1.2 mL, 9.0 mmol)
in anhydrous DMF (35 mL) cooled at 0 8C, TBAI (222 mg, 0.6 mmol)
was added followed by the addition of NaH (60% in mineral oil,
480 mg, 12 mmol) under vigorous stirring. After 10 min the ice
bath was removed and the reaction was allowed to warm to r.t. and
stirred for additional 6 h. The reaction mixture was then cooled to
0 8C and the excess of NaH was carefully quenched with water. The
mixture was acidiﬁed (pH = 2) adding 1 M HCl and extracted with
EtOAc (3  30 mL); the combined organic phases were washed
with brine (10 mL) dried over MgSO4, ﬁltered and concentrated
under reduced pressure. The crude was puriﬁed by ﬂash
chromatography (Hexane/Et2O 9:1) to give the desired product
18 (2.37 g, 72%) as a pale yellow oil. Rf 0.82 (Hexane/EtOAc 1:1); 1H
NMR (400 MHz, CDCl3) d: 1.07 (s, 9H), 1.32 (s, 3H), 1.37 (s, 3H), 3.82
(m, 4H), 4.57 (d, J = 2.9 Hz, 2H), 4.67 (d, J = 4.0 Hz, 1H), 5.90 (d,
J = 4.0 Hz, 1H), 6.89 (d, J = 8.6 Hz, 2H), 7.28 (d, J = 8.6 Hz, 2H), 7.42
(m, 6 H), 7.67 (d, J = 6.8 Hz, 4H); 13C NMR (100 MHz, CDCl3) d: 19.3,
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114.0, 129.6, 133.2, 133.4, 135.7, 135.7, 159.5; MS (ESI), calculated
m/z C32H40O6Si 548 [M]
+, found m/z (relative intensity) 549
[M+H]+ (100).
4.8. (3S,4S,5R)-5-{[(tert-butyldiphenylsilyl)oxy]methyl}-4-[(4-
methoxyphenyl)methoxy]oxolane-2,3-diol (19)
Compound 18 (1.0 g, 1.8 mmol) was dissolved in DCM (50 mL)
and the solution was cooled to 0 8C. TFA (50% in water, 20 mL) was
added under vigorous stirring and the reaction mixture was
allowed to warm to r.t. After 3 h the mixture was quenched by
careful addition of small portions of solid NaHCO3. Water was
added and the mixture was extracted with EtOAc (3  30 mL). The
organic layer was washed with brine, dried over MgSO4, ﬁltered
and the solvent evaporated under reduced pressure. The crude
product was puriﬁed by ﬂash chromatography (Hexane/EtOAc 1:1)
to give a mixture of two anomers (481 mg, 52%) as a colourless oil.
Rf 0.71 (Hexane/EtOAc 1:1); 1H NMR (400 MHz, CDCl3) d: 1.06 (s,
4.5H), 1.08 (s, 4.5H), 3.58 (ddd, J = 11.2, 3.9, 1.9 Hz, 1H), 3.81 (s,
1.5H), 3.83 (s, 1.5H), 3.85 (m, 1H), 4.09 (m, 2.5H), 4.32 (bs, 0.5H),
4.51 (m, 1H), 4.64 (m, 1H), 5.34 (bs, 1H), 6.91 (m, 2H), 7.27 (m, 2H),
7.46 (m, 6H), 7.64 (m, 2H), 7.69 (m, 2H); 13C NMR (100 MHz, CDCl3)
d: 26.7, 26.8, 55.3, 64.2, 64.7, 71.6, 72.0, 76.2, 76.3, 82.6, 82.7, 84.0,
84.3, 97.7, 103.9, 113.9, 114.1, 128.0, 128.7, 128.8, 129.5, 129.7,
130.1, 130.2, 131.6, 132.0, 135.6, 135.7, 136.7, 159.4, 159.6; MS
(ESI), calculated m/z C29H36O6Si 508 [M]
+, found m/z (relative
intensity) 531 [M+Na]+ (100).
4.9. (3S,4R,5R)-2-(acetyloxy)-5-{[(tert-
butyldiphenylsilyl)oxy]methyl}-4-[(4-
methoxyphenyl)methoxy]oxolan-3-yl acetate (20)
To a solution of 19 (480 mg, 0.94 mmol) in anhydrous pyridine
(3 mL), acetic anhydride (0.50 mL, 5.20 mmol) was added drop
wise and the mixture was stirred overnight. The volatile
components were evaporated under reduced pressure, EtOAc
(20 mL) was added and the mixture was washed with 0.5 M HCl
(10 mL), saturated NaHCO3 and brine. The organic layer was dried
over MgSO4, ﬁltered and the solvent evaporated under reduced
pressure. The mixture of two anomers 20 was obtained (557 mg,
100%) as a pale yellow oil and was used without further
puriﬁcation. Rf 0.4 (Hexane/EtOAc 6:4); 1H NMR (400 MHz, CDCl3)
d: 1.04 (s, 4.5H), 1.09 (s, 4.5H), 1.90 (s, 1.5H), 2.04 (s, 1.5H), 2.08 (s,
1.5H), 2.13 (s, 1.5H), 3.80 (m, 2H), 3.81 (s, 1.5H), 3.82 (s, 1.5H), 4.14
(m, 1H), 4.29 (m, 0.5H), 4.40 (m, 0.5H), 4.54 (d, J = 4.7 Hz, 1H), 4.57
(d, J = 2 Hz, 2H), 4.69 (d, J = 11.6 Hz, 1H), 5.27 (m, 1H), 6.21 (s,
0.5H), 6.38 (d, J = 4.7 Hz, 0.5H), 6.87 (m, 2H), 7.24 (m, 2H), 7.42 (m,
6H), 7.66 (m, 4H); 13C NMR (100 MHz, CDCl3) d: 20.6, 20.8, 21.0,
21.2, 26.7, 26.8, 55.2, 55.3, 62.6, 64.0, 72.0, 72.2, 77.2, 77.4, 79.3,
81.3, 82.0, 82.3, 85.7, 93.8, 100.2, 113.9, 125.3, 127.7, 127.8, 127.9,
129.1, 129.3, 129.5, 129.7, 129.8, 129.9, 133.0, 133.1, 133.2, 133.3,
135.5, 135.6, 135.7, 159.4, 169.4, 169.7; MS (ESI), calculated m/z
C33H40O8Si 592 [M]
+, found m/z (relative intensity) [M+Na]+ 615
[M+Na]+ (40), 593 [M+H]+ (100).
4.10. (2S,3S,4R,5R)-5-{[(tert-butyldiphenylsilyl)oxy]methyl}-4-[(4-
methoxyphenyl)methoxy]-2-(2-nitro-1H-imidazol-1-yl)oxolan-3-yl
acetate (21)
2-Nitroimidazole (85 mg, 0.75 mmol) and bis(triethylsilyl)a-
mine (580 mg, 1.50 mmol) were reﬂuxed in anhydrous pyridine
(1.5 mL) for 30 min. The volatiles were removed under high
vacuum distillation. The remaining solid was dissolved in
anhydrous CH3CN (3 mL) and a solution of 20 (345 mg, 0.58 mmol)
in anhydrous CH3CN (2 mL) was added. The mixture was cooled to20 8C and TESOTf 1 M in DCM (0.6 mL, 0.60 mmol) was added
drop wise under stirring. The reaction was warmed to 8 8C and
stirred at this temperature for 3 h. A saturated solution of NaHCO3
(2 mL) was added and the mixture was extracted with EtOAc
(3  20 mL). The organic phase was washed with brine (5 mL),
dried over MgSO4, ﬁltered and the solvent was removed under
reduced pressure. The crude product was puriﬁed by ﬂash
chromatography (Hexane/EtOAc 7:3) to give compound 21
(295 g, 76%) as a white waxy solid. Rf 0.23 (Hexane/EtOAc 7:3);
1H NMR (400 MHz, CDCl3) d: 0.97 (s, 9H), 1.91 (s, 3H), 3.60 (dd,
J = 6.9, 10.8 Hz, 1H) 3.70 (s, 3H), 3.71 (m, 1H), 4.05 (d, J = 1.3 Hz,
1H), 4.42 (dd, J = 27.3, 11.7 Hz, 2H), 4.52 (ddd, J = 2.1, 5.4, 7.2 Hz,
1H), 5.29 (s, 1H), 6.45 (d, J = 8.7 Hz, 2H), 7.00 (d, J = 8.7 Hz, 2H), 7.10
(d, J = 1.2 Hz, 1H), 7.35 (m, 7H), 7.54 (dt, J = 1.2, 8,0 Hz, 4H); 13C
NMR (100 MHz, CDCl3) d: 19.2, 20.7, 26.8, 55.3, 63.3, 71.7, 77.2,
81.4, 81.8, 88.5, 93.2, 113.9, 123.1, 127.8, 128.3, 128.8, 129.4, 130.0,
132.8, 133.0, 135.5, 135.6, 159.5, 169.2; MS (ESI), calculated m/z
C34H39N3O8Si 645 [M]
+, found m/z (relative intensity) 668 [M+Na]+
(30), 646 [M+H]+ (100).
4.11. (2S,3S,4R,5R)-5-(hydroxymethyl)-4-[(4-
methoxyphenyl)methoxy]-2-(2-nitro-1H-imidazol-1-yl)oxolan-3-yl
acetate (22)
Potassium ﬂuoride (183 mg, 3.15 mmol) and benzoic acid
(385 mg, 3.15 mmol) were added to a solution of 21 (295 mg,
0.46 mmol) in anhydrous CH3CN (15 mL). The mixture was
reﬂuxed overnight under vigorous stirring. After cooling the
mixture at 20 8C the solid was ﬁltered over celite, and the pad was
washed with cold CH3CN. The solvent was removed under reduced
pressure and the crude product was puriﬁed by ﬂash chromatog-
raphy (EtOAc 100%) to give compound 22 (178 mg, 95%) as a pale
yellow wax. Rf 0.42 (EtOAc 100%); 1H NMR (400 MHz, CDCl3) d:
2.85 (s, 3H), 3.76 (m, 2H), 3.85 (s, 3H), 4.07 (d, J = 1.9 Hz, 1H), 4.56
(m, 3H), 5.41 (s, 1H), 6.64 (s, 1H), 6.84 (d, J = 8.6 Hz, 2H), 7.08 (d,
J = 8.6 Hz, 2H), 7.17 (d, J = 1.0 Hz, 1H), 7.47 (d, J = 1.0 Hz, 1H); 13C
NMR (100 MHz, CDCl3) d: 20.6, 55.3, 62.3, 72.1, 81.4, 81.8, 88.9,
93.1, 114.0, 123.1, 128.3, 129.4, 159.6, 169.4; MS (ESI), calculated
m/z C18H21N3O8 407 [M]
+, found m/z (relative intensity) 430
[M+Na]+ (40), 408 [M+H]+ (100).
4.12. (2S,3S,4S)-5-formyl-4-[(4-methoxyphenyl)methoxy]-2-(2-
nitro-1H-imidazol-1-yl)oxolan-3-yl acetate (23)
The alcohol 22 (41 mg, 0.10 mmol) was dissolved in a DMSO/
benzene 1:1 mixture (3 mL) cooled to 0 8C. Pyridinium triﬂuor-
oacetate (8.7 mg, 0.05 mmol) and EDC HCl (51.8 mg, 0.27 mmol)
were added and the reaction mixture was allowed to warm to r.t.
After 2 h the reaction was quenched with water and extracted with
EtOAc (3  150 mL). The organic layers were washed with brine
(3  5 mL), dried over MgSO4, ﬁltered and the solvent was
evaporated under reduced pressure. The crude aldehyde 23
(40 mg) was obtained as a pale yellow oil and was used directly
without further puriﬁcation. Rf 0.50 (EtOAc 100%); 1H NMR
(400 MHz, CDCl3) d: 3.82 (s, 3H), 4.23 (s, 1H), 4.50 (m, 3H), 4.92 (s,
1H), 6.71 (s, 1H), 6.84 (d, J = 8.7 Hz, 1H), 7.03 (d, J = 8.7 Hz, 1H), 7.16
(d, J = 1.2 Hz, 1H), 7.45 (d, J = 1.2 Hz, 1H), 9.71 (s, 1H).
4.13. (2S,3S,4R,5R)-5-[hydroxy(2H1)methyl]-4-[(4-
methoxyphenyl)methoxy]-2-(2-nitro-1H-imidazol-1-yl)oxolan-3-yl
acetate (24)
The crude aldehyde 23 was dissolved in ethanol (1 mL), cooled
at 0 8C and NaBD3CN (5.6 mg, 0.09 mmol) was added. The pH was
adjusted to 4.5 by adding one or two drops of acetic acid and the
mixture was allowed to warm to r.t. and stirred overnight. The
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was dissolved in EtOAc (20 mL). The organic layer was washed
with water (5 mL), brine (5 mL), dried over MgSO4, ﬁltered and
concentrated under reduced pressure. The crude product was
puriﬁed by ﬂash chromatography (EtOAc 100%) to give compound
24 (30.6 mg, 75% over two steps) as a white foam. Rf 0.42 (EtOAc
100%); 1H NMR (400 MHz, CDCl3): d: 2.19 (s, 3H), 3.78 (m, 4H), 4.06
(d, J = 2.1 Hz, 1H), 4.53 (m, 3H), 5.41 (s, 1H), 6.65 (s, 1H), 6.85 (d,
J = 8.6 Hz, 2H), 7.09 (d, J = 8.6 Hz, 2H), 7.18 (d, J = 1.0 Hz, 1H), 7.48
(d, J = 1.0 Hz, 1H); 13C NMR (100 MHz, CDCl3): d: 20.6, 55.3, 62.0 (t,
J = 23.2 Hz, D), 72.1, 81.4, 81.8, 88.8, 93.1, 114.0, 123.1, 128.4,
129.4, 159.6, 169.3; MS (ESI), calculated m/z C18H20DN3O8 408
[M]+, found m/z (relative intensity) 431 [M+Na]+ (35), 409 [M+H]+
(100).
4.14. (2S,3S,4S,5S)-5-[ﬂuoro(2H1)methyl]-4-[(4-
methoxyphenyl)methoxy]-2-(2-nitro-1H-imidazol-1-yl)oxolan-3-yl
acetate (25a)
To an ice cooled solution of 24 (15 mg, 0.04 mmol) in anhydrous
DCM (0.2 mL), DAST (6.5 mL, 0.048 mmol) was added drop wise
under stirring. After 10 min the reaction was slowly warmed to r.t.
and stirred for additional 30 min. The mixture was then cooled to
0 8C and MeOH (0.06 mL) was added to quench the reaction. The
solvent was removed under reduced pressure and the crude
product was ﬁltered over silica (Hexane/EtOAc 1:9) to give
compound 25a (5.8 mg, 35%) as a pale yellow oil. Rf 0.73 (EtOAc
100%); 1H NMR (400 MHz, CDCl3) d: 2.17 (s, 3H), 3.80 (s, 3H), 4.51
(m, 3H), 4.58 (m, 4H), 5.39 (s, 1H), 6.63 (s, 1H), 6.83 (d, J = 8.7 Hz,
2H), 7.05 (d, J = 8.7 Hz, 2H), 7.15 (d, J = 1.1 Hz, 1H); 7.45 (d,
J = 0.9 Hz, 1H); 19F NMR (376.45 MHz, CDCl3) d: 227.8; 13C NMR
(100 MHz, CDCl3): 20.7, 55.3, 72.1, 81.0, 81.6, 86.2, 87.6, 93.1,
114.0, 122.9, 123.1, 128.4, 129.5, 159.6, 169.3; MS (ESI), calculated
m/z C18H19DFN3O7 410 [M]
+, found m/z (relative intensity) 433
[M+Na]+ (33), 411 [M+H]+ (100).
4.15. (2S,3S,4S,5S)-5-[ﬂuoro(2H1)methyl]-4-hydroxy-2-(2-nitro-1H-
imidazol-1-yl)oxolan-3-yl acetate (26a)
Compound 25a (5.8 mg, 0.014 mmol) was dissolved in an
acetone/water 4:1 mixture (0.5 mL) then a solution of CAN
(15.5 mg, 0.028 mmol) in water (0.2 mL) was added drop wise
under stirring. After 30 min another portion of CAN (15.5 mg,
0.028 mmol) in water (0.2 mL) was added. After additional 30 min
a saturated solution of NaHCO3 (1 mL) was added and the mixture
was extracted with EtOAc (3  10 mL). The organic layers were
washed with brine (3  2 mL), dried over MgSO4, ﬁltered and the
solvent was evaporated under reduced pressure. The crude
product was puriﬁed by ﬂash chromatography (Hexane/EtOAc
2:8) to give compound 26a (3.8 mg, 93%) as a waxy solid. Rf 0.62
(EtOAc 100%); 1H NMR (400 MHz, CDCl3) d: 2.20 (s, 3H), 4.39 (m,
1H), 4.56 (m, 1H), 4.63 (m, 1H), 5.19 (t, J = 1.0 Hz, 1H), 6.70 (d,
J = 2.1 Hz, 1H), 7.20 (s, 1H), 7.47 (s, 1H); 19F NMR (376.45 MHz,
CDCl3) d: -229.57;
13C NMR (100 MHz, CDCl3) d: 20.7, 75.5 (d,
J = 6.0 Hz), 85.7, 85.7, 85.9 (d, J = 20.3 Hz), 92.2, 122.4, 128.6, 170.7;
MS (ESI), calculated m/z C10H11DFN3O6 290 [M]
+, found m/z
(relative intensity) 313 [M+Na]+ (40), 291 [M+H]+ (100).
4.16. (2S,3S,4S,5S)-5-(ﬂuoromethyl)-4-[(4-
methoxyphenyl)methoxy]-2-(2-nitro-1H-imidazol-1-yl)oxolan-3-yl
acetate (25b)
Synthesized following the same procedure for obtaining 25a.
Starting from 22, compound 25b (28 mg, 35%) was obtained as a
pale yellow oil. Rf 0.73 (EtOAc 100%); 1H NMR (400 MHz, CDCl3) d:2.16 (s, 3H), 3.79 (s, 3H), 4.05 (m, 1H), 4.41 (m, 1H), 4.51 (m, 3H),
4.68 (m, 1H), 5.38 (s, 1H), 6.63 (s, 1H), 6.82 (d, J = 8.7 Hz, 2H), 7.05
(d, J = 8.7 Hz, 2H), 7.14 (d, J = 1.0 Hz, 1H), 7.41 (d, J = 1.0 Hz); 19F
NMR (376.45 MHz, CDCl3) d: 228.36; 13C NMR (100 MHz, CDCl3)
d: 20.5, 55.2, 71.8, 80.8, 81.5, 86.5, 88.7, 93.2, 114.0, 122.8, 128.4,
129.5; MS (ESI), calculated m/z C18H20FN3O7 409 [M]
+, found m/z
(relative intensity) [M+Na]+ 432 (55), 410 [M+H]+ (100).
4.17. (2S,3S,4S,5S)-5-(ﬂuoromethyl)-4-hydroxy-2-(2-nitro-1H-
imidazol-1-yl)oxolan-3-yl acetate (26b)
Synthesized following the same procedure for obtaining 26a.
Starting from 25b, compound 26b was obtained (18 mg, 94%) as a
pale yellow wax. Rf 0.62 (EtOAc 100%); 1H NMR (400 MHz, CDCl3)
d: 2.19 (s, 3H), 4.38 (m, 1H), 4.60 (m, 3H), 5.19 (t, J = 1.8 Hz, 1H),
6.72 (d, J = 1.8 Hz, 1H), 7.18 (s, 1H), 7.48 (s, 1H); 19F NMR
(376.45 MHz, CDCl3) d: 229.24; 13C NMR (100 MHz, CDCl3) d:
20.7, 75.4 (d, J = 5.8 Hz), 81.4 (d, J = 175 Hz), 85.3, 86.3 (d,
J = 19.9 Hz), 93.4, 122.6, 128.5, 170.7; MS (ESI), calculated m/z
C10H12FN3O6 291 [M]
+, found m/z (relative intensity) 314 [M+Na]+
(40), 292 [M+H]+ (100).
4.18. (2S,3S,4S,5S)-2-(ﬂuoromethyl)-5-(2-nitro-1H-imidazol-1-
yl)oxolane-3,4-diol (FAZA, 1)
Synthesized following the same procedure for obtaining 2.
Starting from 26b, compound 1 was obtained (14 mg, 95%) as a
white solid. 1H NMR (400 MHz, CD3OD) d: 4.13 (t, J = 2.1 Hz, 1H),
4.33 (s, 1H), 4.56 (m, 1H), 4.66 (m, 2H), 6.48 (d, J = 1.0 Hz, 1H), 7.16
(d, J = 1.0 Hz, 1H), 7.69 (d, J = 1.0 Hz, 1H); 19F NMR (376.45 MHz,
CD3OD) d: 227.2; 13C NMR (100 MHz, CD3OD) d: 75.8 (d, J = 5.6),
82.2 (d, J = 170 Hz), 82.2, 87.7 (d, J = 20.6 Hz), 95.5, 123.8, 126.9;
MS (ESI), calculated m/z C8H10FN3O5 247 [M]
+, found m/z (relative
intensity) [M+Na]+ 270 (100).
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